Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511)
Year: 2020
Type: article
Abstract: We examined acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) events among 9679 women treated for breast cancer on four adjuvant Alliance for Clinical Trials in Oncology trials with >90 months of follow-up in order to better characterize the risk for AML/MDS in older patients receiving anthracyclines.
DOI: 10.17615/6ase-tn66
Authors: Muss,, Jatoi,, Citron,, Winer,, Lafky,, Shulman,, Seisler,, Kimmick,, Berry,, Cohen,, Freedman, Rachel A., Partridge,, Sloan,, Carey,, Hurria,, Buzdar,, Suman,, Hudis,, Foster,, Klepin,
Institution: University of North Carolina at Chapel Hill
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4300187771